Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP)
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Sponsor: AstraZeneca
This PHASE1 trial investigates Breast Neoplasm Malignant Female and Breast Neoplasms, Triple-Negative and is currently completed. AstraZeneca leads this study, which shows 15 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Dec 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 10 earlier versions
-
Nov 2022 — Dec 2023 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE1
-
Nov 2018 — Nov 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Institut Curie
For direct contact, visit the study record on ClinicalTrials.gov .